GlassScriptPhysician profile
Aaron K Metcalf
NPI 1164582862
$2,468.14
in general payments reported to CMS, 2019-2025
19 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.03 · 2020: $43.18 · 2021: $34.33 · 2022: $145 · 2023: $895 · 2024: $746 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $641.66 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $338.43 | 2023-2025 | |
| Lilly USA, LLC | $258.58 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $174.61 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.29 | 2022-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $133.16 | 2022-2023 | |
| Exact Sciences Corporation | $117.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.27 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $98.44 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $95.98 | 2024-2025 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $63.65 | 2024-2025 | Eliquis, Camzyos |
| Inogen, INC. | $49.84 | 2023-2025 | Inogen At Home Stationary Concentrator |
| Phathom Pharmaceuticals, INC. | $45.08 | 2024-2025 | Voquezna |
| Lundbeck LLC | $42.02 | 2023-2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $38.80 | 2024-2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.07 | 2025 | Veozah |
| Alnylam Pharmaceuticals INC. | $25.46 | 2025 | Givlaari |
| Axsome Therapeutics, INC. | $19.56 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.49 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Metcalf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.